58. Hypertrophic cardiomyopathy
92 clinical trials,   126 drugs   (DrugBank: 35 drugs),   40 drug target genes,   141 drug target pathways
Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03259113 (ClinicalTrials.gov) | August 16, 2017 | 19/8/2017 | Insertable Cardiac Monitors in Hypertrophic Cardiomyopathy | EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic CardioMyopathy | Hypertrophic Cardiomyopathy | Device: Insertable cardiac monitor | Region Gävleborg | St. Jude Medical;Norrlands University Hospital | Recruiting | 18 Years | 65 Years | All | 30 | N/A | Sweden |
2 | NCT02862600 (ClinicalTrials.gov) | August 1, 2016 | 8/8/2016 | Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure | A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function | Cardiomyopathy, Hypertrophic;Cardiomyopathy, Hypertrophic, Familial | Drug: Perhexiline;Device: Use of bioanalytical assay to monitor plasma levels of perhexiline | Heart Metabolics Limited | NULL | Terminated | 18 Years | N/A | All | 35 | Phase 2 | United States |